Author, year | Study type | Region/study year | Resistance | CRKP mortality (%) | CSKP mortality (%) | P value | Carbapenemases | Infection type | ICU | SOT |
---|---|---|---|---|---|---|---|---|---|---|
Vardakas (2015) [11] | Retrospective cohort study | Greece 2006.1–2009.10 | CLSI 2010 | 58/80 (72.5) | 14/24 (58.3) | 0.19 | NA | BSI:44/65 | 80 | 0 |
Brizendine (2015) [16] | Retrospective cohort study | USA 2011.12–2013.10 | CLSI 2012 | 16/157 (10.2) | NA | NA | NA | UTI:16/157 | 0 | 0 |
Pouch (2015) [12] | Nested case–control study | USA  2007.1–2010.12 | CLSI 2009 | 6/20 (30) | 8/80 (10) | 0.03 | NA | UTI:6/20 | 0 | 20 |
Ny (2015) [13] | Retrospective cohort study | USA  2011.1–2013.12 | NA | 7/48 (14.6) | 5/48 (10.4) | 0.76 | NA | UTI:2/27 | 0 | 0 |
Girmenia (2015) [39] | Retrospective cohort study | Italy  2010.1–2013.7 | NA | 65/112 (58.1) | NA | NA | NA | Any infection:65/112 | 0 | 112 |
Hoxha (2015) [14] | Prospective matched cohort study | Italy  2012.11–2013.7 | Eucast Guideline | 30/49 (61) | 10/49 (20) | NA | NA | Any infection:30/49 | 0 | 0 |
Cubero (2015) [15] | Retrospective cohort study | Spain  2010.10–2012.12 | EUCAST 2015 | 8/20 (40) | 1/9 (11.1) | NA | NA | Any infection:8/20 | 0 | 0 |
Chang (2015) [40] | Retrospective study | Taiwan  2012.1–2012.12 | CLSI 2012 | 21/41 (51.2) | NA | NA | KPC:6/8 | Any infection:21/41 | 41 | 0 |
Chen (2015) [68] | Retrospective study | Taiwan  2014.4–10 | NA | 12/41 (29.3) | NA | NA | NA | Any infection:12/41 | 0 | 0 |
Madrigal (2015) [66] | Retrospective study | Spain  2014.5–9 | NA | 2/5 (40) | NA | NA | NA | Any infection:2/5 | 0 | 0 |
Bias (2015) [70] | Retrospective, observational cohort study | USA  –2014.8 | NA | 5/30 (16.7) | NA | NA | NA | Any infection:5/30 | 0 | 30 |
Katsiari (2015) [67] | Prospective, observational study | Greece  2010.4–2012.3 | CLSI 2012 | 14/32 (43.8) | NA | NA | KPC:11/28VIM:3/5 | BSI:9/16 | 32 | 0 |
Maristela Freire (2015) [69] | Retrospective cohort study | Brazil  2009.1–2013.12 | CLSI 2012 | 13/31 (41.9) | NA | NA | KPC:13/31 | BSI:7/11 UTI:1/10 | 0 | 31 |
Brizendine (2015) [16] | Retrospective cohort study | USA  2006–2012 | NA | 4/22 (18) | 1/64 (1.5) | NA | NA | UTI:4/22 | 0 | 22 |
Sarah Welch (2015) [65] | Retrospective cohort study | USA | NA | 19/51 (37.3) | NA | NA | NA | Pneumonia:19/51 | 0 | 0 |
van Duin (2014) [16] | Prospective, multi-center, observational study | USA  2011.12–2013.3 | CLSI | 26/114 (22.8) | NA | NA | NA | BSI:5/26 | 0 | 0 |
Simkins (2014) [17] | Retrospective case–control study | USA  2006.1–2010.12 | NA | 6/13 (46.2) | 3/39 (7.7) | 0.005 | NA | Any infection:6/13 | 0 | 13 |
Viviana Gómez Rueda (2014) [18] | Case–case–control study | Colombia  2008.1–2011.1 | CLSI | 31/61 (50.8) | 20/61 (32.8) | NA | NA | Any infection:31/61 | 0 | 0 |
Christoph Lübbert (2014) [71] | Retrospective study | Germany  2010.9–2011.9 | NA | 7/8 (87.5) | NA | NA | KPC:7/8 | Any infection:7/8 | 0 | 8 |
Qureshi (2014) [42] | Retrospective cohort study | USA  2009.1–2012.10 | NA | 0/21 (0.00) | NA | NA | NA | UTI:0/21 | 0 | 0 |
Mouloudi (2014) [43] | Retrospective cohort study | Greece  2008.1–2011.12 | EUCAST 2012 | 14/17 (82.4) | NA | NA | NA | BSI:14/17 | 17 | 17 |
Bulent Aydinl (2014) [72] | Retrospective analysis | Turkey  2012.1–2013.11 | NA | 2/5 (40) | NA | NA | NA | Any infection:2/5 | 0 | 5 |
Gallagher (2014) [44] | Retrospective case–case–control study | USA  2005.6–2010.10 | CLSI 2009 | 19/43 (44.2) | NA | NA | NA | BSI:19/43 | 0 | 0 |
Graziella Hanna Pereira (2013) [47] | Retrospective cohort study | Brazil  2008.10–2010.10 | CLSI 2010 | 16/33 (48) | NA | NA | NA | BSI:9/11 UTI:3/21 Pneumonia:3/7 | 0 | 0 |
Orsi (2013) [19] | Case–case–control study | Italy  2008.7–2011.6 | EUCAST | 25/65 (38.5) | 12/43 (27.9) | NA | KPC:14/36 | Any infection:25/65 | 0 | 0 |
Kontopidou (2013) [48] | Retrospective cohort study | Greece  2009.9–2010.6 | CLSI 2010 | 29/127 (22.8) | NA | NA | NA | Any infection:29/127 | 127 | 0 |
Hussein (2013) [20] | Retrospective case control study | Israel  2006.1–2008.12 | CLSI 2006 | 45/103 (43.7) | 62/214 (29) | NA | NA | BSI:45/103 | 0 | 0 |
Luci Correa (2013) [22] | Matched case–control study | Brazil  2006.1–2008.8 | CLSI 2009 | 10/20 (50) | 11/40 (27.5) | 0.085 | NA | Any infection:10/20 | 0 | 0 |
Clancy (2013) [49] | Single-center, retrospective study | USA  2008.8–2011.7 | CLSI 2012 | 3/17 (17.6) | NA | NA | NA | BSI:3/17 | 0 | 17 |
Cober (2013) [21] | Retrospective cohort study | USA  2006–2009 | NA | 8/19 (42.1) | 7/46 | 0.005 | NA | BSI:8/19 | 0 | 19 |
Grossi (2013) [73] | Retrospective cohort study | Italy  2009.1–2012.10 | NA | 11/36 (30.6) | NA | NA | NA | Any infection:11/36 | 0 | 36 |
Cicora (2013) [50] | Observational, retrospective study | Argentina  2011.4–2012.6 | CLSI 2010 | 2/6 (33.3) | NA | NA | KPC:2/6 | UTI:2/6 | 0 | 6 |
Paola Di Carlo (2013) [46] | Prospective case series study | Italy  2011,8–2012.8 | EUCAST | 12/30 (40) | NA | NA | KPC:12/30 | Any infection:12/30 | 30 | 0 |
Fligou (2013) [88] | Retrospective cohort study | Greece | CLSI | 21/48 (43.8) | NA | NA | KPC:21/48 | BSI:21/48 | 48 | 0 |
Rose (2012) [74] | Retrospective, cohort study | USA  2006–2011 | NA | 20/44 (45.5) | NA | NA | NA | BSI:20/44 | 0 | 0 |
Sanchez-Romero (2012) [51] | Retrospective cohort study | Spain  2009.1–2009.12 | CLSI 2011 | 13/28 (46.4) | NA | NA | VIM:13/28 | Any infection:13/28 | 28 | 0 |
Liu (2012) [23] | Matched case–control study | Taiwan  2007.1–2009.12 | CLSI 2009 | 15/25 (60) | 20/50 | 0.102 | NA | BSI:15/25 | 0 | 0 |
Kalpoe (2012) [52] | Retrospective cohort study | USA  2005.1–2006.10 | NA | 10/14 (71.4) | NA | NA | NA | Any infection:10/14 | 0 | 14 |
Borer (2012) [53] | Retrospective case control study | Israel  2007.5–2010.1 | CLSI 2006 | 13/42 (31) | NA | NA | NA | Any infection:13/42 | 0 | 0 |
Bergamasco (2012) [54] | Retrospective cohort study | Brazil  2009.7–2010.2 | CLSI 2009 | 5/12 (41.7) | NA | NA | KPC:2/12 | Any infection:5/12 | 0 | 12 |
Ben-David (2012) [24] | Retrospective cohort study | Israel  2006.1–2006.12 | CLSI 2006 | 29/42 (69.1) | 45/150 (30) | <0.001 | NA | BSI:29/42 | 0 | 0 |
Balkhy (2012) [55] | Retrospective/prospective surveillance study | Saudi Arabia  2009.9–2010.8 | CLSI 2009 | 8/20 (40) | NA | NA | NA | Any infection:8/20 | 0 | 0 |
Jason Gallagher (2011) [75] | A retrospective, cohort study | USA  2006–2011 | NA | 24/44 (54.5) | NA | NA | NA | BSI:24/44 | 0 | 0 |
Pereira (2011) [56] | Retrospective cohort study | Brazil  2008.10–2010.8 | CLSI 2010 | 9/22 (40.9) | NA | NA | NA | Any infection:9/22 | 0 | 0 |
Orsi (2011) [25] | Retrospective case control study | Italy  2008.7–2009.12 | EUCAST | 11/28 (39.3) | 12/43 | NA | NA | Any infection:11/28 | 0 | 0 |
Neuner (2011) [57] | Retrospective cohort study | USA  2007.1–2009.5 | CLSI 2009 | 35/60 (58.3) | NA | NA | NA | BSI:35/60 | 0 | 0 |
Diana Gaviria (2011) [31] | Retrospective matched case–control study | USA  2009.4–2011.12 | CLSI | 1/19 (5.3) | 3/38 (7.9) | NA | NA | Any infection:1/19 | 0 | 0 |
Cuzon (2011) [59] | Retrospective cohort study | France  2010.4–2010.6 | CLSI 2010 | 5/7 (71.4) | NA | NA | NA | Any infection:5/7 | 0 | 0 |
Elisa Maria Beirão (2011) [58] | Retrospective cohort study | Brazil  2008.1–2008.12 | CLSI 2009 | 3/6 (50) | NA | NA | KPC:3/6 | Any infection:3/6 | 0 | 0 |
Nguyen (2010) [60] | Retrospective cohort study | USA  2004.1–2008.9 | CLSI | 29/48 (60.4) | NA | NA | NA | BSI:29/48 | 0 | 0 |
Vardakas (2010) [76] | Retrospective cohort study | Greece  2006.1–2009.9 | NA | 42/56 (75) | NA | NA | NA | Any infection:42/56 | 56 | 0 |
Mouloudi (2010) [26] | Retrospective nested case–control study | Greece  2007.1–2008.12 | CLSI 2007 | 25/37 (67.6) | 9/22 (40.9) | 0.03 | KPC: 15/19 VIM:10/18 | BSI:25/37 | 0 | 0 |
Gregory (2010) [61] | Retrospective case–control study | Puerto Rico  2008.2–2008.9 | CLSI 2009 | 7/19 (36.8) | NA | NA | NA | Any infection:7/19 | 0 | 0 |
Balandin Moreno (2010) [77] | Retrospective cohort study | Spain  2009.7–2010.4 | NA | 2/8 (25) | NA | NA | VIM:2/8 | Any infection:2/8 | 8 | 0 |
Gasink (2009) [27] | Case–control study | USA  2006.10–2008.4 | NA | 18/56 (32.1) | 85/863 (9.8) | NA | KPC:18/56 | Any infection:18/56 | 0 | 0 |
Daikos (2009) [28] | Prospective observational study | Greece  2005.2–2006.3 | CLSI 2004 | 6/14 (42.9) | 25/148 (16.9) | NA | VIM:6/14 | BSI:6/14 | 0 | 0 |
Borer (2009) [62] | Matched retrospective, historical cohort study | Israel  2005.10–2008.10 | CLSI 2006 | 30/64 (46.9) | NA | NA | NA | BSI:23/32 | 0 | 0 |
Schwaber (2008) [29] | Retrospective cohort study | Israel  2003–2006 | CLSI 2005 | 21/48 (43.8) | 7/56 (12.5) | NA | NA | Any infection:21/48 | 0 | 0 |
Patel (2008) [30] | Retrospective matched case–control | USA  2004.7–2006.6 | CLSI 2006 | 48/99 (48.5) | 20/99 (20.2) | <0.001 | NA | Any infection:48/99 | 0 | 0 |
Falagas (2007) [32] | Retrospective matched case–control study | Greece  2000.10–2006.5 | NA | 16/53 (30.2) | 18/53 (34) | 0.83 | NA | Any infection:16/53 | 0 | 0 |
Woodford (2004) [63] | Retrospective cohort study | USA  2000.4–2001.4 | CLSI | 8/14 (57.1) | NA | NA | KPC:8/14 | Any infection:8/14 | 14 | 0 |
Muhammad Ahmad. (1999) [64] | Retrospective cohort study | USA  1994.12–1995.11 | CLSI 1994 | 6/8 (75) | NA | NA | NA | Any infection:6/8 | 8 | 0 |